Literature DB >> 15385932

Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.

J H Cho-Vega1, G Z Rassidakis, H M Amin, P Tsioli, K Spurgers, Y K Remache, F Vega, A H Goy, F Gilles, L Jeffrey Medeiros.   

Abstract

Using a cDNA microarray, we found that suppressor of cytokine signaling 3 (SOCS3) is highly expressed in anaplastic lymphoma kinase (ALK)+ anaplastic large cell lymphoma (ALCL) cell lines. As SOCS3 is induced by activated signal transducer and activator of transcription 3 (STAT3), and ALK activates STAT3, we hypothesized that SOCS3 may play a role in ALK+ ALCL pathogenesis via the Janus kinase 3 (JAK3)-STAT3 pathway. Using ALCL cell lines, we show by coimmunoprecipitation experiments that SOCS3 physically binds with JAK3 in vitro, and that JAK3 inhibition by WHI-P154 downregulates SOCS3 expression. Western blot analysis confirmed expression of SOCS3 and also showed coexpression of phosphorylated (activated) STAT3 (pSTAT3). Direct sequencing of the SOCS3 gene showed no mutations or alternative splicing. In ALCL tumors that were assessed by immunohistochemistry, nine of 12 (75%) ALK+ tumors were SOCS3 positive and eight (67%) coexpressed pSTAT3. In comparison, 18 of 25 (72%) ALK-- tumors were SOCS3 positive and seven (28%) coexpressed pSTAT3. These results show that SOCS3 is overexpressed in ALCL, attributable to JAK3-STAT3 activation and likely related to ALK in ALK+ tumors. However, SOCS3 is also expressed in tumors that lack STAT3 and ALK suggesting alternative mechanisms of upregulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385932     DOI: 10.1038/sj.leu.2403495

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

Review 1.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

2.  Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy.

Authors:  Dongjun Lee; Ying-Hua Wang; Demetrios Kalaitzidis; Janani Ramachandran; Homare Eda; David B Sykes; Noopur Raje; David T Scadden
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

3.  JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis.

Authors:  George Z Rassidakis; Athanasios Thomaides; Coralyn Atwell; Richard Ford; Dan Jones; Francois-Xavier Claret; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

4.  Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression.

Authors:  Emily C Brantley; L Burton Nabors; G Yancey Gillespie; Youn-Hee Choi; Cheryl Ann Palmer; Keith Harrison; Kevin Roarty; Etty N Benveniste
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 5.  SOCS regulation of the JAK/STAT signalling pathway.

Authors:  Ben A Croker; Hiu Kiu; Sandra E Nicholson
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

Review 6.  Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas.

Authors:  Emily C Brantley; Etty N Benveniste
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

7.  Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling.

Authors:  Hua Xiong; Zhao-Fei Chen; Qin-Chuan Liang; Wan Du; Hui-Min Chen; Wen-Yu Su; Guo-Qiang Chen; Ze-Guang Han; Jing-Yuan Fang
Journal:  J Cell Mol Med       Date:  2009-09       Impact factor: 5.310

Review 8.  The role of suppressors of cytokine signalling in human neoplasms.

Authors:  Walid Sasi; Anup K Sharma; Kefah Mokbel
Journal:  Mol Biol Int       Date:  2014-03-16

Review 9.  Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Authors:  Suzanne D Turner; Giorgio Inghirami; Roberto N Miranda; Marshall E Kadin
Journal:  Am J Pathol       Date:  2019-10-11       Impact factor: 4.307

10.  Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.

Authors:  Archana Anantharaman; Terence Friedlander; David Lu; Rachel Krupa; Gayatri Premasekharan; Jeffrey Hough; Matthew Edwards; Rosa Paz; Karla Lindquist; Ryon Graf; Adam Jendrisak; Jessica Louw; Lyndsey Dugan; Sarah Baird; Yipeng Wang; Ryan Dittamore; Pamela L Paris
Journal:  BMC Cancer       Date:  2016-09-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.